Seoul National University

Lg Chemical Ltd.

Cellid Co., Ltd.

Snu Rdb Foundation

Korea Food Research Institute

Viromed Co., Ltd.

Lg Chem-investment Ltd.

Chang-Yuil Kang

Yeonseok Chung

Hyun-Jeong Ko

Yeon-Jeong Kim

Taeho Lee

Sun-Young Chang

Hyo Jeong Hong

Sanghee Kim

Dong-Hyeon Kim

Tae-Hee Lee

Mi-Jeong Park

Joon Youb Lee

Tae-Kyo Park

Hye-Kyung Chang

Kwang-Yul Moon

Dong-Hwa Shon

Hyoung Jin Kang

Young-Myeong Kim

Hyun-Ho Chung

Young-Leem Oh

Byung-Seok Kim

Young Jun Kang

Sung Kwan Yoon

Dong Jae Baek

Sun Ok Yun

Sung Sup Park

Joong-Gon Kim

Tae-Gwon Oh

Kwang-Soo Shin

Bongju Park

Eunice Eun-Kyeong Kim

Hee-Soon Shin

Min-Jung Bae

Ok-Hee Chai

Dae-Woon Choi

Gye-Young Choi

Jeong-Hae Rho

Jeong-Ryong Do

Jung-Mi Lee

Hyun-Jun Youn

Yoon-Sook Lee

Kyoo-A Lee

Minjae Cho

Kyung-Chul Lee

Sung-Youl Ko

Chang-Hee Min

Sun-Young Jung

The present invention relates to a novel adenoviral vector not including a replication competent adenovirus. A recombinant E1/E3/E4-deleted adenoviral vector, of the present invention, in which an antigenic protein and an E4orf6 gene are inserted in an E1 gene-deleted region, has adenovirus productivity, degree of antigen expression, neutralizing antibody production amount, and T cell induction ability that are similar to those of a control group, and thus can be effectively used as a carrier for various vaccines for diseases or anti-cancer vaccines.

Adenoviral vector not including replication competent adenovirus, and use thereof

Disclosed in the present application are: a method for preparing in vitro/ex vivo antigen-specific cytotoxic T-cells by using B cells treated with biological response modifier; and a use thereof. The cytotoxic T-cells prepared by the method of the present application can be used advantageously for treating infectious disease and cancer and the like.

Method for preparing antigen-specific cytotoxic T-cells by using activated B-cells and use thereof

The present invention provides a composition for preventing, improving, or treating Th1-mediated immune diseases or Th2-mediated immune diseases, an antihistamine composition, and an anti-inflammatory composition. The present invention provides a method for preventing, improving, or treating Th1-mediated immune diseases or Th2-mediated immune diseases, a method for inhibiting the release of histamine, and a method for preventing, improving, or treating inflammatory disorders. The composition according to the present invention has excellent inhibitory activities for IL-4 generation, the degranulation of mast cells, COX-2, 15-NOX, and the passing of allergens from through an intestinal epithelial cell layer, or an excellent Treg cell inducing activity. Further, the present invention provides a detailed mechanism of action of a natural substance and a food-drived antiallergenic substance, and provides stability, a reduction in production costs, and improved convenience of use by using a natural substance as a material.

Composition for preventing, improving, or treating immune diseases comprising natural extracts as active ingredients

The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with &#x3b1;-galactosylceramide (&#x3b1;GalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.

Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen

Disclosed are novel &#x3b1;-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation methods thereof, and pharmaceutical compositions for use in an immune adjuvant containing the same as an active ingredient. The derivatives, in which the amide moiety of &#x3b1;-GalCer is bioisosterically replaced with a triazole moiety, direct cytokine secretion toward IL-4 rather than IFN-&#x3b3;and thus can be used as a therapeutic for autoimmune diseases regulated by IL-4, such as type 1 diabetes and multiple sclerosis.

&#x3b1;-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient

The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.

Her-2/neu DNA vaccine having anti-cancer activity

The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with &#x3b1;-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

B cell-based vaccine loaded with the ligand of natural killer T cell and antigen

The present invention provides to an isoxazoline derivative of formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof, and the use of the derivative in inhibiting the activity of caspases. The present invention also provides a pharmaceutical composition for preventing inflammation and apoptosis which comprise the isoxazoline derivative, pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof and the process for preparing the same. The derivative according to the present invention can be effectively used in treating diseases due to caspases, such as, for example the disease in which cells are abnormally died, dementia, cerebral stroke, AIDS, diabetes, gastric ulcer, hepatic injury by hepatitis, sepsis, organ transplantation rejection reaction and anti-inflammation.

Isoxazoline derivative and a process for the preparation thereof

The present invention is directed to humanized antibodies that specifically bind the protein 4-1BB. The antibodies can be made by grafting of the complementarity determining regions (CDR's) of mouse monoclonal antibody to human 4-1BB to the remaining portions of a human antibody and by making further amino acid replacements. In addition, a pharmaceutical composition that includes the humanized antibody can be made and can be used to treat autoimmune diseases to suppress an immune response. The humanized antibody of the invention has high affinity for human 4-1BB, and exhibits sequence similarity to human antibody. As a result, the pharmaceutical composition of the present invention can be used to treat autoimmune disease and act as an immunosuppressant in humans without much side-effect.

Humanized antibody specific for human 4-1BB

Monoclonal antibody specific for human 4-1BB and cell line producing same

Growing community of inventors

Seoul, South Korea

Chang-Yuil Kang